---
figid: PMC5992820__13058_2018_983_Fig1_HTML
figtitle: Simplified schematic diagram of the pathways described in this study
organisms:
- Bos taurus
- Oryctolagus cuniculus
- Armoracia rusticana
- Olea europaea
- Homo sapiens
- Mus musculus
pmcid: PMC5992820
filename: 13058_2018_983_Fig1_HTML.jpg
figlink: /pmc/articles/PMC5992820/figure/Fig1/
number: F1
caption: Simplified schematic diagram of the pathways described in this study. a Growth
  factor signalling (IGFR and ERBB) leads to activation of PI3K and phosphorylation
  of AKT. AKT inhibits TCS1/2, resulting in upregulation of mTORC1. In parallel, mTORC1
  can also be upregulated by the RAS-RAF-MEK-ERK signalling pathway. ERK phosphorylates
  and inactivates TCS2 also leading to mTORC1 activation. S6 K1 activity increases
  as a result of mTORC1 activation. S6 K1 suppresses mTORC2 and IRS1. ER is also a
  target of S6 K1 leading to phosphorylation of serine 167. b Inhibition of mTORC1
  with everolimus suppresses S6 K1 removing the negative feedback loop causing a rise
  in IRS1 and AKT activity via loss of suppression on mTORC2. Increased AKT activity
  suppresses TCS1/2 and increases expression of growth factor receptors (ERBB2/3)
  enhancing RAS-RAF-ERK signalling. c The dual blockade of ERBBs (neratinib) and mTORC1
  signalling (everolimus) may suppress the two feedback loops described in b. Yellow
  shows normal mTORC signalling cascade; blue represents activated proteins; red represents
  inhibited proteins; dotted lines show loss of normal feedback loops
papertitle: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth
  factor, and oestrogen receptor signalling pathways in endocrine-resistant breast
  cancer.
reftext: Ricardo Ribas, et al. Breast Cancer Res. 2018;20:44.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8999083
figid_alias: PMC5992820__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Bos taurus
- Oryctolagus cuniculus
redirect_from: /figures/PMC5992820__F1
ndex: f4ee1e43-df13-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5992820__13058_2018_983_Fig1_HTML.html
  '@type': Dataset
  description: Simplified schematic diagram of the pathways described in this study.
    a Growth factor signalling (IGFR and ERBB) leads to activation of PI3K and phosphorylation
    of AKT. AKT inhibits TCS1/2, resulting in upregulation of mTORC1. In parallel,
    mTORC1 can also be upregulated by the RAS-RAF-MEK-ERK signalling pathway. ERK
    phosphorylates and inactivates TCS2 also leading to mTORC1 activation. S6 K1 activity
    increases as a result of mTORC1 activation. S6 K1 suppresses mTORC2 and IRS1.
    ER is also a target of S6 K1 leading to phosphorylation of serine 167. b Inhibition
    of mTORC1 with everolimus suppresses S6 K1 removing the negative feedback loop
    causing a rise in IRS1 and AKT activity via loss of suppression on mTORC2. Increased
    AKT activity suppresses TCS1/2 and increases expression of growth factor receptors
    (ERBB2/3) enhancing RAS-RAF-ERK signalling. c The dual blockade of ERBBs (neratinib)
    and mTORC1 signalling (everolimus) may suppress the two feedback loops described
    in b. Yellow shows normal mTORC signalling cascade; blue represents activated
    proteins; red represents inhibited proteins; dotted lines show loss of normal
    feedback loops
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erbb2
  - Erbb3
  - Igf1r
  - Irs1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Pdk1
  - Pdpk1
  - Zhx2
  - Akt1
  - Map2k1
  - Map2k2
  - Tsc1
  - Tsc2
  - Mapk3
  - Mapk1
  - Rps6kb1
  - pk
  - ERBB2
  - ERBB3
  - IGF1R
  - IRS1
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDK1
  - PDPK1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - MAP2K1
  - MAP2K2
  - TSC1
  - CCL26
  - TSC2
  - MAPK3
  - MAPK1
  - RPTOR
  - RPS6KB1
  - Neratinib
  - Everolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
